Literature DB >> 28593878

Microbiota abnormalities and the therapeutic potential of probiotics in the treatment of mood disorders.

Adiel C Rios1, Pawan Kumar Maurya1, Mariana Pedrini1, Maiara Zeni-Graiff1, Elson Asevedo1, Rodrigo B Mansur1, Andrea Wieck1, Rodrigo Grassi-Oliveira1, Roger S McIntyre1, Mirian A F Hayashi1, Elisa Brietzke1.   

Abstract

Major depressive disorder (MDD) and bipolar disorder (BD) are among the leading causes of burden and disability worldwide. Despite intensified research efforts to improve the treatment options and remission rates in mood disorders, no disease modifying treatment exists for these disorders. Accumulating evidence implicates the involvement of the gut microbiota in processes relevant to etiopathology of central nervous system-based disorders. The objective of this article was to critically evaluate the evidence supporting the link between gastrointestinal microbiota and mood disorders and to discuss the potential benefits of using probiotics in the treatment of MDD and BD. The concept of psychobiotics, which is bacterial-based interventions with mental health benefit, is emerging in the field. On the other hand, while probiotics might potentially represent a significant advance, specific roles of microbiota in the pathophysiology of mood disorders still need further investigation along with intervention studies.

Entities:  

Keywords:  bipolar disorder; major depression disorder; microbiome; microbiota; mood disorders; probiotics

Mesh:

Year:  2017        PMID: 28593878     DOI: 10.1515/revneuro-2017-0001

Source DB:  PubMed          Journal:  Rev Neurosci        ISSN: 0334-1763            Impact factor:   4.353


  8 in total

1.  Nitrated meat products are associated with mania in humans and altered behavior and brain gene expression in rats.

Authors:  Seva G Khambadkone; Zachary A Cordner; Faith Dickerson; Emily G Severance; Emese Prandovszky; Mikhail Pletnikov; Jianchun Xiao; Ye Li; Gretha J Boersma; C Conover Talbot; Wayne W Campbell; Christian S Wright; C Evan Siple; Timothy H Moran; Kellie L Tamashiro; Robert H Yolken
Journal:  Mol Psychiatry       Date:  2018-07-18       Impact factor: 15.992

2.  Pharmacological restoration of gut barrier function in stressed neonates partially reverses long-term alterations associated with maternal separation.

Authors:  Marion Rincel; Maïwenn Olier; Amandine Minni; Camille Monchaux de Oliveira; Yann Matime; Eric Gaultier; Isabelle Grit; Jean-Christophe Helbling; Anna Maria Costa; Amandine Lépinay; Marie-Pierre Moisan; Sophie Layé; Laurent Ferrier; Patricia Parnet; Vassilia Theodorou; Muriel Darnaudéry
Journal:  Psychopharmacology (Berl)       Date:  2019-05-23       Impact factor: 4.530

Review 3.  Targeting the immune system in the treatment of bipolar disorder.

Authors:  Joshua D Rosenblat
Journal:  Psychopharmacology (Berl)       Date:  2019-02-13       Impact factor: 4.530

Review 4.  Inflammation-driven brain and gut barrier dysfunction in stress and mood disorders.

Authors:  Ellen Doney; Alice Cadoret; Laurence Dion-Albert; Manon Lebel; Caroline Menard
Journal:  Eur J Neurosci       Date:  2021-05-17       Impact factor: 3.698

Review 5.  "Immune Gate" of Psychopathology-The Role of Gut Derived Immune Activation in Major Psychiatric Disorders.

Authors:  Leszek Rudzki; Agata Szulc
Journal:  Front Psychiatry       Date:  2018-05-29       Impact factor: 4.157

Review 6.  Gut feeling: randomized controlled trials of probiotics for the treatment of clinical depression: Systematic review and meta-analysis.

Authors:  Viktoriya Nikolova; Syed Yawar Zaidi; Allan H Young; Anthony J Cleare; James M Stone
Journal:  Ther Adv Psychopharmacol       Date:  2019-06-26

Review 7.  Updated Review and Meta-Analysis of Probiotics for the Treatment of Clinical Depression: Adjunctive vs. Stand-Alone Treatment.

Authors:  Viktoriya L Nikolova; Anthony J Cleare; Allan H Young; James M Stone
Journal:  J Clin Med       Date:  2021-02-08       Impact factor: 4.241

Review 8.  Gut-Brain Axis and Mood Disorder.

Authors:  Lu Liu; Gang Zhu
Journal:  Front Psychiatry       Date:  2018-05-29       Impact factor: 4.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.